Skip to main content

Table 2 Prevalence of 17 individual Charlson comorbidities at baseline and at the end of the study

From: Effects of longitudinal changes in Charlson comorbidity on prognostic survival model performance among newly diagnosed patients with hypertension

  Baseline At End of Study
  n % n %
Charlson Comorbidities
Myocardial infarction 27,304 (6.02) 53,774 (11.85)
Congestive heart failure 26,041 (5.74) 60,426 (13.32)
Peripheral vascular disease 13,399 (2.95) 33,863 (7.46)
Cerebrovascular disease 23,881 (5.26) 56,297 (12.41)
Hemiplegia or paraplegia 3738 (0.82) 8536 (1.88)
Dementia 8890 (1.96) 31,659 (6.98)
Chronic pulmonary disease 70,227 (15.48) 122,785 (27.06)
Rheumatologic disease 8161 (1.80) 18,223 (4.02)
Peptic ulcer disease 11,674 (2.57) 27,142 (5.98)
Diabetes without chronic complications 31,098 (6.85) 58,389 (12.87)
Diabetes with chronic complications 7503 (1.65) 23,390 (5.16)
Renal disease 10,231 (2.25) 34,560 (7.62)
Any malignancy, including leukemia and lymphoma 26,853 (5.92) 69,637 (15.35)
Metastatic solid tumor 4784 (1.05) 18,231 (4.02)
Mild liver disease 6524 (1.44) 16,860 (3.72)
Moderate or severe liver disease 968 (0.21) 2782 (0.61)
AIDS/HIV 230 (0.05) 407 (0.09)
Number of Charlson Comorbidities
0 285,417 (63.2) 179,802 (39.6)
1-2 140,101 (28.1) 181,353 (40.0)
≥3 28,216 (8.7) 92,579 (20.4)